Legend Innovation Life Science Fund Adds Accelero Biostructures as a Preferred Technology Partner
Legend Innovation Life Science Fund has named Accelero Biostructures a Preferred Technology Partner, giving portfolio companies access to advanced structural biology and AI-driven drug discovery platforms designed to accelerate early-stage development.
FORT LEE, N.J. — Legend Innovation Life Science Fund, LLC (“Legend”) and Accelero Biostructures (“Accelero”) announced a strategic partnership designating Accelero as a Preferred Technology Partner for the fund.
The collaboration is intended to accelerate drug discovery and development across Legend’s portfolio companies by providing access to Accelero’s high-throughput structural biology and artificial intelligence drug design platforms.
Accelero specializes in high-throughput protein X-ray crystallography and will provide eligible Legend portfolio companies with access to its proprietary ABS-Services™ and ABS-OneStep™ platforms.
These technologies support precise hit identification and validation of target engagement across a wide range of biological targets, including targets traditionally considered difficult to address with drug-based therapies.
“This partnership with Legend represents a significant opportunity to expand the impact of our crystallography-driven drug discovery platforms,” said Debanu Das, Co-Founder and CEO of Accelero Biostructures.
“By combining our expertise with Legend’s portfolio of innovative life science companies, we aim to dramatically accelerate the drug discovery process and bring novel therapies to patients faster.”
Dr. Syngbum (Ben) Kim, Managing Partner of Legend Innovation Life Science Fund, added:
“Accelero’s advanced structural biology and AIDD platforms align perfectly with our fund’s mission to drive innovation in drug discovery. As one of our Preferred Technology Partners, Accelero will play a crucial role in enhancing the drug development efforts of our portfolio companies, potentially reducing timelines and improving the quality of drug candidates.”
The partnership is expected to provide Legend’s portfolio companies with additional capabilities during early-stage drug discovery.
By supporting more efficient hit-to-lead discovery, the collaboration may help companies develop and optimize critical drug-candidate characteristics, including target affinity, potency, selectivity, and absorption, distribution, metabolism, and excretion properties.
About Legend Innovation Life Science Fund
Legend Innovation Life Science Fund is an investment fund dedicated to advancing life sciences and healthcare technologies.
The fund supports entrepreneurs in bringing innovative solutions from concept to commercialization, with a focus on areas including neuroscience, obesity, cancer, diabetes, and regenerative medicine.
Website: legendlifescience.com
About Accelero Biostructures
Founded in 2015, Accelero Biostructures specializes in high-throughput protein X-ray crystallography for structure-based drug discovery and structural biology.
Its proprietary platforms generate rapid and precise protein-ligand interaction data, helping accelerate the process from initial screening to drug-candidate selection.
Website: accelerobio.com
Media Contact
Dr. Syngbum (Ben) Kim
Managing Partner
Legend Innovation Life Science Fund, LLC
Phone: +1 201-383-5370
Email: info@legendlifescience.com
Website: legendlifescience.com